In this ongoing, multicenter, double-blind, phase 3 trial, outpatients with COVID-19 symptoms for 5 days or less who were at high risk for disease progression were randomized to 1 sotrovimab infusion (dose, 500 mg) or placebo.
from Google Alert - health https://ift.tt/30E9JFo
via IFTTT
0 comments:
Post a Comment